RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

My point was not so much that the scenario I laid out was necessarily the case, but rather that we can't stipulate that the data will be good, let alone favorable. For the record: I don't know much of anything about pain pathways, etc.

Given that there are a number of confounding issues here that BP analysts will (I hope) factor in (arousal response as a surrogate for RD, mismatched dosages in RD2 and RD1, etc.), it still seems possible that to me that with a far-from-perfect outcome, cor can nonetheless enter into a partnership. My questions are:

On the basis of RD2 alone, is a partnership possible?

If RD-1 is ambiguous, will cor have the option of raising funds via a PIPE or other mechanisms, assuming share-price remains at or below current levels?